New drug trial aims to protect kids from rare swelling disorder
NCT ID NCT07298447
Summary
This study is testing a drug called donidalorsen in children aged 2 to 12 who have hereditary angioedema (HAE), a rare condition that causes sudden, severe swelling. The main goal is to see if the drug is safe and well-tolerated in children, and to measure how it works in their bodies. Researchers will also track how many HAE attacks the children have while on the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ionis Investigative Site
RECRUITINGSanta Monica, California, 90404, United States
-
Ionis Investigative Site
RECRUITINGSt Louis, Missouri, 63141, United States
-
Ionis Investigative Site
RECRUITINGCincinnati, Ohio, 45236, United States
Conditions
Explore the condition pages connected to this study.